Alimera Sciences Inc (ALIM.O)

ALIM.O on Consolidated Issue listed on NASDAQ Global Market

5.11USD
6 Mar 2015
Change (% chg)

$0.21 (+4.29%)
Prev Close
$4.90
Open
$4.85
Day's High
$5.17
Day's Low
$4.72
Volume
203,574
Avg. Vol
182,353
52-wk High
$8.36
52-wk Low
$4.50

ALIM.O

Chart for ALIM.O

About

Alimera Sciences, Inc. is a biopharmaceutical company. The Company researches, develops and commercializes the prescription of ophthalmic pharmaceuticals. The Company focuses on diseases affecting the back of the eye. The Company’s product is ILUVIEN, an implant providing a therapeutic effect for up to 36 months in the treatment... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $234.77
Shares Outstanding(Mil.): 44.30
Dividend: --
Yield (%): --

Financials

  ALIM.O Industry Sector
P/E (TTM): -- 38.98 40.20
EPS (TTM): -1.13 -- --
ROI: -98.02 17.01 16.34
ROE: -- 17.52 17.27
Search Stocks

Alimera, pSivida eye implant finally wins U.S. approval

- Alimera Sciences Inc and pSivida Corp said the U.S. Food and Drug Administration approved their vision-loss treatment Iluvien, following three rejections.

26 Sep 2014

UPDATE 1-Alimera, pSivida eye implant finally wins U.S. approval

Sept 26 - Alimera Sciences Inc and pSivida Corp said the U.S. Food and Drug Administration approved their vision-loss treatment Iluvien, following three rejections.

26 Sep 2014

Alimera's eye implant Iluvien wins FDA approval

Sept 26 - The Food and Drug Administration has approved Alimera Sciences Inc's and pSivida Corp's vision-loss treatment Iluvien after three rejections.

26 Sep 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$49.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks